These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32883237)

  • 1. Lifetime survival and medical costs of lung cancer: a semi-parametric estimation from South Korea.
    Park HY; Hwang J; Kim DH; Jeon SM; Choi SH; Kwon JW
    BMC Cancer; 2020 Sep; 20(1):846. PubMed ID: 32883237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden of lung cancer: A retrospective cohort study in South Korea, 2002-2015.
    Jeon SM; Kwon JW; Choi SH; Park HY
    PLoS One; 2019; 14(2):e0212878. PubMed ID: 30794674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of life expectancy, loss-of-life expectancy, and lifetime healthcare expenditures for schizophrenia in Taiwan.
    Lêng CH; Chou MH; Lin SH; Yang YK; Wang JD
    Schizophr Res; 2016 Mar; 171(1-3):97-102. PubMed ID: 26811230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs for 5-year lung cancer survivors in a tertiary care hospital in South Korea.
    Park YS; Kim SH; Park SK; Park BJ; Kim YT; Lee SM; Yim JJ; Yoo CG; Kim YW; Han SK; Shim YS; Yang SC
    Lung Cancer; 2010 May; 68(2):299-304. PubMed ID: 19646776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601).
    Decroisette C; Monnet I; Berard H; Quere G; Le Caer H; Bota S; Audigier-Valette C; Geriniere L; Vernejoux JM; Chouaid C;
    J Thorac Oncol; 2011 Mar; 6(3):576-82. PubMed ID: 21270669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable incremental cost-effectiveness ratio for lung cancer screening in Italy.
    Veronesi G; Navone N; Novellis P; Dieci E; Toschi L; Velutti L; Solinas M; Vanni E; Alloisio M; Ghislandi S
    Lung Cancer; 2020 May; 143():73-79. PubMed ID: 32234647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Observations in lung cancer over multiple decades: an analysis of outcomes and cost at a single high-volume institution.
    Lanuti M; Hong HJ; Ali S; Stock C; Temel J; Mathisen D; Michaelson JS
    Eur J Cardiothorac Surg; 2014 Aug; 46(2):254-61; discussion 261. PubMed ID: 24453265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
    Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of Life-Year Loss and Lifetime Costs for Different Stages of Colon Adenocarcinoma in Taiwan.
    Chen PC; Lee JC; Wang JD
    PLoS One; 2015; 10(7):e0133755. PubMed ID: 26207912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-of-illness trend of schizophrenia in South Korea from 2006 to 2016.
    Jo M; Kim HJ; Rim SJ; Lee MG; Kim CE; Park S
    PLoS One; 2020; 15(7):e0235736. PubMed ID: 32673350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost of lung cancer in Turkey.
    Cakir Edis E; Karlikaya C
    Tuberk Toraks; 2007; 55(1):51-8. PubMed ID: 17401794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Projections of the cost of cancer care in the United States: 2010-2020.
    Mariotto AB; Yabroff KR; Shao Y; Feuer EJ; Brown ML
    J Natl Cancer Inst; 2011 Jan; 103(2):117-28. PubMed ID: 21228314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis.
    Puri V; Crabtree TD; Kymes S; Gregory M; Bell J; Bradley JD; Robinson C; Patterson GA; Kreisel D; Krupnick AS; Meyers BF
    J Thorac Cardiovasc Surg; 2012 Feb; 143(2):428-36. PubMed ID: 22169443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung cancer in Argentina: a modelling study of disease and economic burden.
    Alcaraz A; Rodriguez-Cairoli F; Colaci C; Silvestrini C; Gabay C; Espinola N
    Public Health; 2024 Jul; 232():86-92. PubMed ID: 38759472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Economic Burden of Breast Cancer Survivors in Korea: A Descriptive Study Using a 26-Month Micro-Costing Cohort Approach.
    You CH; Kang S; Kwon YD
    Asian Pac J Cancer Prev; 2019 Jul; 20(7):2131-2137. PubMed ID: 31350976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
    Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease burden of hospitalized community-acquired pneumonia in South Korea: Analysis based on age and underlying medical conditions.
    Choi MJ; Song JY; Noh JY; Yoon JG; Lee SN; Heo JY; Yoon JW; Jo YM; Cheong HJ; Kim WJ
    Medicine (Baltimore); 2017 Nov; 96(44):e8429. PubMed ID: 29095281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the lifelong health impact and financial burdens of different types of lung cancer.
    Yang SC; Lai WW; Su WC; Wu SY; Chen HH; Wu YL; Hung MC; Wang JD
    BMC Cancer; 2013 Dec; 13():579. PubMed ID: 24308346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
    Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
    Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model.
    Moldaver D; Hurry M; Evans WK; Cheema PK; Sangha R; Burkes R; Melosky B; Tran D; Boehm D; Venkatesh J; Walisser S; Orava E; Grima D
    Lung Cancer; 2020 Jan; 139():185-194. PubMed ID: 31812889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.